dexefaroxan has been researched along with oxidopamine in 1 studies
| Studies (dexefaroxan) | Trials (dexefaroxan) | Recent Studies (post-2010) (dexefaroxan) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 15 | 0 | 4 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | dexefaroxan (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bizot, JC; Colpaërt, F; Drouin, C; Glowinski, J; Marien, M; Tassin, JP; Villégier, AS | 1 |
1 other study(ies) available for dexefaroxan and oxidopamine
| Article | Year |
|---|---|
Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Benzopyrans; Cerebellum; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Hyperkinesis; Imidazoles; Locomotion; Male; Mice; Mice, Knockout; Oxidopamine; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Time Factors | 2003 |